Hemodynamic Effects of Interfacility Dexmedetomidine Infusions During Transport of Patients with Alpha-2-adrenergic Agonist Withdrawal.
- 1Temple Transport Team, Philadelphia, Pennsylvania.
- 2Temple University Hospital, Department of Emergency Medicine, Division of Emergency Medical Services, Philadelphia, Pennsylvania.
- 3Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania.
Abstract
Background
In the Philadelphia region, there has been an increase in the potency of illicit opioids as well as the addition of nonopioid adulterants. Currently, medetomidine, a veterinary anesthetic that acts as an alpha-2-adrenergic agonist, is a common adulterant in the illicit opioid supply, causing both unique overdose and withdrawal syndromes. Although opioid withdrawal alone is not deadly, with added adulterants, especially medetomidine, this is no longer the case. Dexmedetomidine is an alpha-2-adrenergic agonist frequently used for sedation in the emergency department and intensive care unit. Dexmedetomidine is also used off-label to treat the life-threatening withdrawal from alpha-2-agonists.Objective
This study describes the dosing and hemodynamic effects associated with the interfacility administration of dexmedetomidine in patients with alpha-2 adrenergic agonist withdrawal. Secondarily, we describe the safety of dexmedetomidine in this patient population.Methods
We conducted a retrospective case review of patients receiving dexmedetomidine infusions in the interfacility setting for presumed alpha-2-adrenergic agonist withdrawal. Demographic data, dosing, and vital signs were analyzed descriptively.Results
Over a six-month period, of 217 cases identified, 182 contained complete hemodynamic data. The average age was 39.5 years, and 67% were male. The average transport time was 15.7 minutes (range, 5-40 minutes). The mean dexmedetomidine infusion rate was 1.32 (0.31) mcg/kg/hr. The average mean arterial pressure decreased from 122.1 mm Hg (21.7) at the time of initial patient contact to 118.3 mm Hg (21.7) (mean difference, 3.80; 95% CI, 1.96-5.64) at final patient interaction. Heart rate also showed a minimal change from 104.9 (23.7) to 103.6 (21.8) beats/min (mean 1.3; 95% CI, -0.48 to 3.08). No cases of severe hypotension or clinically significant bradycardia requiring intervention were documented (one-sided 95% CI, 0-1.7%).Conclusion
In this case series of patients, prehospital dexmedetomidine infusions to treat alpha-2-agonist withdrawal were associated with stable hemodynamics without significant bradycardia or hypotension. These findings support the safety of dexmedetomidine infusions for interfacility transport and provide a rationale for examining whether advanced life support clinicians can safely transport patients receiving dexmedetomidine infusions for this indication.
Related
- Intraoperative hemodynamic changes in patients receiving dexmedetomidine for general anesthesia.
- National Trends in Emergency Department Boarding and Interfacility Transfers by Rurality
- Interfacility Variation in Diagnosis and Tocolysis for Threatened Preterm Labor and Its Association With Gestational Age Threshold for Neonatal Intensive Care Unit Admission: A Cross-Sectional Survey of Perinatal Centers in the Chugoku-Shikoku Region of Western Japan.
- Neuroblastoma-derived small extracellular vesicles retaincellular identity and adrenergic/mesenchymal state signatures
- Monitoring of brown adipose tissue with β3-adrenergic receptor agonist using [18F]FDG PET/CT and [123I]mIBG SPECT/CT
BibTeX
@article{goldstein2026hemodynamic,
title = {{Hemodynamic Effects of Interfacility Dexmedetomidine Infusions During Transport of Patients with Alpha-2-adrenergic Agonist Withdrawal.}},
author = {Scott Goldstein and Nathaniel Zahustecher and Derek Isenberg and Eric Rosen and Celine Bennett},
journal = {The western journal of emergency medicine},
year = {2026},
month = sep,
doi = {10.5811/westjem.62953},
url = {https://europepmc.org/article/MED/42900939},
note = {CC BY},
}
RIS
TY - JOUR
TI - Hemodynamic Effects of Interfacility Dexmedetomidine Infusions During Transport of Patients with Alpha-2-adrenergic Agonist Withdrawal.
AU - Scott Goldstein
AU - Nathaniel Zahustecher
AU - Derek Isenberg
AU - Eric Rosen
AU - Celine Bennett
PY - 2026
DA - 2026/09/09
JO - The western journal of emergency medicine
DO - 10.5811/westjem.62953
UR - https://europepmc.org/article/MED/42900939
AB - Background In the Philadelphia region, there has been an increase in the potency of illicit opioids as well as the addition of nonopioid adulterants. Currently, medetomidine, a veterinary anesthetic that acts as an alpha-2-adrenergic agonist, is a common adulterant in the illicit opioid supply, causing both unique overdose and withdrawal syndromes. Although opioid withdrawal alone is not deadly, with added adulterants, especially medetomidine, this is no longer the case. Dexmedetomidine is an alpha-2-adrenergic agonist frequently used for sedation in the emergency department and intensive care unit. Dexmedetomidine is also used off-label to treat the life-threatening withdrawal from alpha-2-agonists.Objective This study describes the dosing and hemodynamic effects associated with the interfacility administration of dexmedetomidine in patients with alpha-2 adrenergic agonist withdrawal. Secondarily, we describe the safety of dexmedetomidine in this patient population.Methods We conducted a retrospective case review of patients receiving dexmedetomidine infusions in the interfacility setting for presumed alpha-2-adrenergic agonist withdrawal. Demographic data, dosing, and vital signs were analyzed descriptively.Results Over a six-month period, of 217 cases identified, 182 contained complete hemodynamic data. The average age was 39.5 years, and 67% were male. The average transport time was 15.7 minutes (range, 5-40 minutes). The mean dexmedetomidine infusion rate was 1.32 (0.31) mcg/kg/hr. The average mean arterial pressure decreased from 122.1 mm Hg (21.7) at the time of initial patient contact to 118.3 mm Hg (21.7) (mean difference, 3.80; 95% CI, 1.96-5.64) at final patient interaction. Heart rate also showed a minimal change from 104.9 (23.7) to 103.6 (21.8) beats/min (mean 1.3; 95% CI, -0.48 to 3.08). No cases of severe hypotension or clinically significant bradycardia requiring intervention were documented (one-sided 95% CI, 0-1.7%).Conclusion In this case series of patients, prehospital dexmedetomidine infusions to treat alpha-2-agonist withdrawal were associated with stable hemodynamics without significant bradycardia or hypotension. These findings support the safety of dexmedetomidine infusions for interfacility transport and provide a rationale for examining whether advanced life support clinicians can safely transport patients receiving dexmedetomidine infusions for this indication.
SN - 1936-900X
SN - 1936-9018
ER -